Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 4INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 47Thoracic 9Head & Neck 5Other solid neoplasm 4Tumor-Agnostic 3Genitourinary 3Sarcoma 1Myeloid 1CNS 1

Conditions

Neoplasms 3Neoplasm Metastasis 2

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Panitumumab × Tumor-Agnostic × Clear all
NCT07021898 2025-12-03

BOREALIS-1

Erasca, Inc.

Phase 1 Recruiting
200 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT06983743 2025-09-11

AURORAS-1

Erasca, Inc.

Phase 1 Recruiting
200 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT00091806 2009-07-10

Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

Amgen

Phase 1 Completed
86 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡